DK3301107T3 - Nye peptider der bindes til typer af mhc klasse ii og deres anvendelse ved diagnosticering og behandling - Google Patents

Nye peptider der bindes til typer af mhc klasse ii og deres anvendelse ved diagnosticering og behandling Download PDF

Info

Publication number
DK3301107T3
DK3301107T3 DK17200662.9T DK17200662T DK3301107T3 DK 3301107 T3 DK3301107 T3 DK 3301107T3 DK 17200662 T DK17200662 T DK 17200662T DK 3301107 T3 DK3301107 T3 DK 3301107T3
Authority
DK
Denmark
Prior art keywords
diagnostication
types
treatment
mhc class
peptides binding
Prior art date
Application number
DK17200662.9T
Other languages
English (en)
Inventor
Lars Klareskog
Vivianne Malmstström
Original Assignee
Curara Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curara Ab filed Critical Curara Ab
Application granted granted Critical
Publication of DK3301107T3 publication Critical patent/DK3301107T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
DK17200662.9T 2011-04-05 2012-04-05 Nye peptider der bindes til typer af mhc klasse ii og deres anvendelse ved diagnosticering og behandling DK3301107T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472122P 2011-04-05 2011-04-05
SE1150297 2011-04-05
EP12768393.6A EP2694530B1 (en) 2011-04-05 2012-04-05 Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment

Publications (1)

Publication Number Publication Date
DK3301107T3 true DK3301107T3 (da) 2020-05-18

Family

ID=46969450

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17200662.9T DK3301107T3 (da) 2011-04-05 2012-04-05 Nye peptider der bindes til typer af mhc klasse ii og deres anvendelse ved diagnosticering og behandling

Country Status (5)

Country Link
US (4) US20150218546A1 (da)
EP (4) EP2694530B1 (da)
DK (1) DK3301107T3 (da)
ES (1) ES2777502T3 (da)
WO (1) WO2012138294A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2560012T3 (es) * 2011-05-10 2016-02-17 Institut National De La Santé Et De La Recherche Médicale (Inserm) Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
CN106488932B (zh) * 2013-12-20 2020-07-14 财团法人生物技术开发中心 α-烯醇化酶特异性抗体及其在癌症治疗中的使用方法
US9382331B2 (en) * 2013-12-27 2016-07-05 Development Center For Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
WO2015181393A1 (en) * 2014-05-30 2015-12-03 Per-Johan Jakobsson Novel sfti and cyclotide based peptides
CA2984499A1 (en) * 2015-05-29 2016-12-08 Arrowhead Pharmaceuticals, Inc. Biologically cleavable tetrapeptide linking agents
GB201512703D0 (en) * 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520542D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
CN110041404B (zh) * 2019-04-08 2020-10-09 北京大学人民医院(北京大学第二临床医学院) 瓜氨酸化抗原修饰肽及其应用
GB201909774D0 (en) * 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method
EP4021490A4 (en) * 2019-08-30 2023-10-25 Universidad De Chile AUTOANTIGEN PEPTIDES (CALVICIFIV), PRESENTED BY TOLEROGENED DENTRIC CELLS, FOR THE PERSONALIZED TREATMENT OF RHEUMATOID ARTHRITIS
CA3220978A1 (en) * 2021-06-01 2022-12-08 Lars Klareskog Novel peptide mimics and their use
IL310434A (en) 2021-07-29 2024-03-01 Sonoma Biotherapeutics Inc A chimeric extracellular matrix-specific antigen receptor from a destroyer to target regulatory T cells for the treatment of autoimmune diseases
WO2023030407A1 (zh) * 2021-08-31 2023-03-09 首都医科大学附属北京同仁医院 靶向夏科-莱登结晶蛋白的多肽及其应用
WO2023196925A2 (en) * 2022-04-07 2023-10-12 Guardant Health, Inc. Methods and systems for allele typing

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
WO1996020950A2 (en) * 1995-01-06 1996-07-11 Immulogic Pharmaceutical Corporation Compositions and methods for treating rheumatoid arthritis
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
EP1420806B1 (en) * 2001-07-12 2013-05-01 Rikard Holmdahl Antibody detection method using triple polypeptide complexes derived from collagen ii
NL1019540C2 (nl) 2001-12-11 2003-07-01 Stichting Tech Wetenschapp Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit.
EP1332760A1 (en) * 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
CA2518187A1 (en) * 2003-03-07 2004-09-16 London Health Sciences Centre Reseach, Inc. Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
US7393920B2 (en) 2003-06-23 2008-07-01 Cem Corporation Microwave-assisted peptide synthesis
DE602005004902T2 (de) * 2005-06-02 2008-10-16 Entelechon Gmbh Künstliches Protein, Verfahren für absolute Quantifizierung der Proteine und seine Benutzung
FI20050814A0 (fi) 2005-08-11 2005-08-11 Procollagen Oy Menetelmä nivelreumassa muodostuvien kollageeniautovasta-aineiden havaitsemiseksi
EP2008100A4 (en) * 2006-04-18 2009-12-16 Univ Leland Stanford Junior ESTABLISHING ANTIBODY PROFILES FOR DETERMINING PATIENT SENSITIVITY TO TREATMENT
WO2007133702A2 (en) * 2006-05-12 2007-11-22 Cell Signaling Technology, Inc. Reagents for the detection of protein acetylation signaling pathways
US20100047256A1 (en) * 2007-01-25 2010-02-25 Imperial Innovations Limited Methods
WO2008099419A2 (en) * 2007-02-14 2008-08-21 Council Of Scientific & Industrial Research Autoantibodies for protein antigens as markers for cancer of gingivo-buccal complex
US8728744B2 (en) * 2007-10-26 2014-05-20 The Regents Of The University Of California Salivary protein biomarkers for human oral cancer
DE102007059924A1 (de) * 2007-12-03 2009-06-04 Eberhard-Karls-Universität Tübingen Universitätsklinikum Allel- und Isotyp-spezifische Intervention an mit Autoimmunerkrankungen assoziierten MHC-Klasse-II-Molekülen durch Peptide
CA2707132A1 (en) 2007-12-11 2009-06-18 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
WO2010085763A1 (en) * 2009-01-23 2010-07-29 Inova Diagnostics, Inc. Methods for detecting antibodies associated with autoimmune diseases utilizing a three dimensionally heterogeneous peptide antigen
NZ608489A (en) * 2009-03-30 2014-08-29 Nestec Sa Citrullinated peptides for diagnosing and prognosing rheumatiod arthritis
US9695410B2 (en) * 2010-07-15 2017-07-04 Technion Research & Development Foundation Limited Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides
EP2667888A4 (en) * 2011-01-28 2015-11-11 Univ Oregon Health & Science LIGMPHES OF RECOMBINANT T LYMPHOCYTES AND ANTIBODIES BINDING TO LYMPHOCYTES B FOR THE TREATMENT OF AUTOIMMUNE DISEASES
ES2560012T3 (es) * 2011-05-10 2016-02-17 Institut National De La Santé Et De La Recherche Médicale (Inserm) Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias

Also Published As

Publication number Publication date
EP3045468B1 (en) 2020-01-15
EP3412680B1 (en) 2020-11-04
EP3301107A1 (en) 2018-04-04
US20200277357A1 (en) 2020-09-03
EP2694530A1 (en) 2014-02-12
US20200407424A1 (en) 2020-12-31
WO2012138294A1 (en) 2012-10-11
EP3412680A2 (en) 2018-12-12
US20150218546A1 (en) 2015-08-06
EP3045468A3 (en) 2016-09-14
US10774129B2 (en) 2020-09-15
EP2694530A4 (en) 2015-03-18
US20160130323A1 (en) 2016-05-12
ES2777502T3 (es) 2020-08-05
EP2694530B1 (en) 2018-02-14
EP3045468A2 (en) 2016-07-20
EP3301107B1 (en) 2020-05-06
EP3412680A3 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
DK3301107T3 (da) Nye peptider der bindes til typer af mhc klasse ii og deres anvendelse ved diagnosticering og behandling
DK2780375T3 (da) Bindingsmolekyler til bcma og cd3
DK3358011T3 (da) Peptid til inducering af regenerering af væv og anvendelse deraf
DK2890780T3 (da) Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2675827T3 (da) Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
DK2857401T3 (da) Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme
DK2663336T3 (da) Fremgangsmåder og reagenser til effektiv og targeteret afgivelse af terapeutiske molekyler til CXCR4-celler
DK3141542T3 (da) Substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsiltning
DK2852680T3 (da) Fremgangsmåder og processer til ikke-invasiv evaluering af genetiske variationer
DK3181119T3 (da) Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
DK3578201T3 (da) Fremgangsmåder og sammensætninger til naturlige dræberceller
DK2776567T3 (da) Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK2714733T3 (da) Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
DK2742135T4 (da) Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf
DK3363433T3 (da) Fremgangsmåder til reduktion af risikoen for en kardiovaskulær begivenhed i et individ i statinbehandling ved anvendelse af eicosapentaensyreetylester
DK2809795T3 (da) Materialer og fremgangsmåder til syntese af fejlminimerede nukleinsyremolekyler
DK3597749T3 (da) Fremgangsmåder og sammensætninger til rna-dirigeret mål-dna-modificering og til rna-dirigeret modulering af transkription
DK2663864T3 (da) Fremgangsmåde til at vurdere immundiversitet og anvendelse af denne
DK2900061T3 (da) Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
DK2579877T3 (da) Morpholinopyrimidiner og deres anvendelse til terapi
DK4011364T3 (da) Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder)
DK2797957T3 (da) Bindingsmolekyler specifikke for her3 og anvendelser deraf
DK2768321T3 (da) Fremgangsmåder og sammensætninger til induktion af mæthed
DK2917231T3 (da) Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme